JP2016520620A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520620A5 JP2016520620A5 JP2016517065A JP2016517065A JP2016520620A5 JP 2016520620 A5 JP2016520620 A5 JP 2016520620A5 JP 2016517065 A JP2016517065 A JP 2016517065A JP 2016517065 A JP2016517065 A JP 2016517065A JP 2016520620 A5 JP2016520620 A5 JP 2016520620A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pain
- conotoxin peptide
- pharmaceutical composition
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 108050003126 conotoxin Proteins 0.000 claims description 36
- 208000002193 Pain Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 23
- 208000024891 symptom Diseases 0.000 claims description 17
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 230000004054 inflammatory process Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 201000001119 neuropathy Diseases 0.000 claims description 7
- 230000007823 neuropathy Effects 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 206010065390 Inflammatory pain Diseases 0.000 claims description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims description 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 2
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 239000005414 inactive ingredient Substances 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 201000010260 leiomyoma Diseases 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Chemical group [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 8
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Chemical group [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 8
- 235000016491 selenocysteine Nutrition 0.000 description 8
- 229940055619 selenocysteine Drugs 0.000 description 8
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical group [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 7
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 4
- YUIGJDNAGKJLDO-JYJNAYRXSA-N Arg-Arg-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YUIGJDNAGKJLDO-JYJNAYRXSA-N 0.000 description 4
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical group NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Chemical group OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 4
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 4
- WTXQBCCKXIKKHB-JYJNAYRXSA-N Tyr-Arg-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WTXQBCCKXIKKHB-JYJNAYRXSA-N 0.000 description 4
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 4
- 235000013477 citrulline Nutrition 0.000 description 4
- 229960002173 citrulline Drugs 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 108010053037 kyotorphin Proteins 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 208000037816 tissue injury Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000015296 acetylcholine-gated cation-selective channel activity proteins Human genes 0.000 description 1
- 108040006409 acetylcholine-gated cation-selective channel activity proteins Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical group OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000001554 selenocysteine group Chemical group [H][Se]C([H])([H])C(N([H])[H])C(=O)O* 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829633P | 2013-05-31 | 2013-05-31 | |
| US61/829,633 | 2013-05-31 | ||
| US201361843135P | 2013-07-05 | 2013-07-05 | |
| US61/843,135 | 2013-07-05 | ||
| PCT/US2014/040374 WO2014194284A1 (en) | 2013-05-31 | 2014-05-30 | Conotoxin peptides, pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520620A JP2016520620A (ja) | 2016-07-14 |
| JP2016520620A5 true JP2016520620A5 (enExample) | 2017-07-13 |
| JP6681826B2 JP6681826B2 (ja) | 2020-04-15 |
Family
ID=51989449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517065A Expired - Fee Related JP6681826B2 (ja) | 2013-05-31 | 2014-05-30 | コノトキシンペプチド、医薬組成物およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10633417B2 (enExample) |
| EP (1) | EP3003344B1 (enExample) |
| JP (1) | JP6681826B2 (enExample) |
| KR (1) | KR20160019469A (enExample) |
| CN (1) | CN105377286B (enExample) |
| AU (1) | AU2014273883B9 (enExample) |
| CA (1) | CA2913993A1 (enExample) |
| HK (1) | HK1221425A1 (enExample) |
| MX (1) | MX367858B (enExample) |
| TW (1) | TWI686205B (enExample) |
| WO (1) | WO2014194284A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI708790B (zh) * | 2014-11-07 | 2020-11-01 | 美商奇尼塔慢性疼痛有限責任公司 | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 |
| CN105985410B (zh) * | 2015-02-16 | 2019-11-29 | 海南大学 | 芋螺肽、其药物组合物及用途 |
| US10947274B1 (en) * | 2018-05-01 | 2021-03-16 | University Of Utah Research Foundation | Synthetic analgesic peptides of RgIA analogs |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| CN113493502B (zh) * | 2020-04-01 | 2023-09-12 | 广西大学 | α-芋螺毒素肽TxIE、其药物组合物及用途 |
| KR20230031884A (ko) * | 2020-06-03 | 2023-03-07 | 유타대학연구재단 | 형태적으로 제약된 α-RGIA 유사체 |
| CN114805488B (zh) * | 2021-01-29 | 2023-05-30 | 李威 | 一种靶向神经元烟碱型乙酰胆碱受体的新型多肽分子nAChR_BP及其应用 |
| US20240269228A1 (en) * | 2021-06-03 | 2024-08-15 | University Of Utah Research Foundation | Selective penicillamine substitution enables development of a potent analgesic peptide that acts through a non-opioid based mechanism |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4569967A (en) | 1983-10-24 | 1986-02-11 | The Salk Institute For Biological Studies | Synthesis of N-substituted peptide amides |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| US5082670A (en) | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
| DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
| US5854217A (en) | 1992-09-28 | 1998-12-29 | Bearsden Bio, Inc. | Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| DE69423522T2 (de) | 1993-04-27 | 2000-09-21 | Cytotherapeutics, Inc. | Membran aus einem acrylnitrilpolymer |
| EP0708670A4 (en) | 1993-06-23 | 1998-07-01 | Cytotherapeutics Inc | METHOD AND APPARATUS FOR HERMETICALLY CLOSING IMPLANTABLE MEMBRANE ENCAPSULATING DEVICES |
| US5595972A (en) * | 1993-06-29 | 1997-01-21 | University Of Utah Research Foundation | Conotoxin peptides |
| US5432155A (en) * | 1993-06-29 | 1995-07-11 | The Salk Institute For Biological Studies | Conotoxins I |
| US5514774A (en) * | 1993-06-29 | 1996-05-07 | University Of Utah Research Foundation | Conotoxin peptides |
| CA2169292C (en) | 1993-08-12 | 2010-11-23 | E. Edward Baetge | Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules |
| US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
| US5776747A (en) | 1994-07-20 | 1998-07-07 | Cytotherapeutics, Inc. | Method for controlling the distribution of cells within a bioartificial organ using polycthylene oxide-poly (dimethylsiloxane) copolymer |
| US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| IN181898B (enExample) | 1995-06-07 | 1998-10-24 | Cytotherapeutics Inc | |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| AU7204996A (en) | 1995-10-02 | 1997-04-28 | Cytotherapeutics, Inc. | Method for treating amyotrophic lateral sclerosis |
| US5844077A (en) | 1997-04-28 | 1998-12-01 | Cytotherapeutics, Inc. | Use of conantokins for producing analgesia or for neuroprotection |
| US5866682A (en) * | 1997-05-15 | 1999-02-02 | University Of Utah Research Foundation | Conopeptides AuIA, AuIB and AuIC |
| US6265541B1 (en) * | 1997-12-31 | 2001-07-24 | University Of Utah Research Foundation | Uses of α-conotoxin peptides |
| AUPP589598A0 (en) | 1998-09-14 | 1998-10-08 | University Of Queensland, The | Novel peptides |
| CA2361138A1 (en) * | 1999-01-22 | 2000-07-27 | University Of Utah Research Foundation | Alpha-conotoxin peptides |
| US6797808B1 (en) * | 1999-01-29 | 2004-09-28 | University Of Utah Research Foundation | α-conotoxin peptides |
| US6767896B1 (en) * | 1999-01-29 | 2004-07-27 | Cognetix, Inc. | Conotoxin peptides |
| EP1151100A4 (en) * | 1999-02-04 | 2002-07-17 | Univ Utah Res Found | TAU-CONOTOXIN PEPTIDE |
| AU2740401A (en) * | 1999-12-30 | 2001-07-16 | Cognetix, Inc. | O-superfamily conotoxin peptides |
| US6767895B2 (en) * | 2000-06-30 | 2004-07-27 | Cognetix, Inc. | I-superfamily conotoxins |
| JP2004537253A (ja) * | 2000-07-21 | 2004-12-16 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | ミュー−コノペプチド |
| US20030109670A1 (en) | 2001-02-09 | 2003-06-12 | University Of Utah Research Foundation | Cone snail peptides |
| US7387997B2 (en) * | 2004-11-09 | 2008-06-17 | University Of Utah | α-conotoxin MII analogues |
| CA2566832A1 (en) | 2006-04-13 | 2007-10-13 | The University Of Queensland | Cyclised alpha-conotoxin peptides |
| US9284358B2 (en) * | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| WO2008011006A2 (en) | 2006-07-18 | 2008-01-24 | University Of Utah Research Foundation | Methods for treating pain and screening analgesic compounds |
| US8765677B2 (en) * | 2009-09-21 | 2014-07-01 | The University Of Queensland | Omega conotoxin peptides |
| JP6336979B2 (ja) * | 2012-08-07 | 2018-06-06 | ハイナン ユニバーシティ | α−コノトキシンペプチド、その医薬組成物及びそれらの使用 |
-
2014
- 2014-05-30 WO PCT/US2014/040374 patent/WO2014194284A1/en not_active Ceased
- 2014-05-30 EP EP14803477.0A patent/EP3003344B1/en not_active Not-in-force
- 2014-05-30 CN CN201480037106.7A patent/CN105377286B/zh not_active Expired - Fee Related
- 2014-05-30 HK HK16109735.3A patent/HK1221425A1/zh unknown
- 2014-05-30 KR KR1020157036731A patent/KR20160019469A/ko not_active Ceased
- 2014-05-30 CA CA2913993A patent/CA2913993A1/en not_active Abandoned
- 2014-05-30 MX MX2015016492A patent/MX367858B/es active IP Right Grant
- 2014-05-30 JP JP2016517065A patent/JP6681826B2/ja not_active Expired - Fee Related
- 2014-05-30 AU AU2014273883A patent/AU2014273883B9/en not_active Ceased
- 2014-05-30 US US14/894,967 patent/US10633417B2/en active Active
- 2014-05-30 TW TW103119136A patent/TWI686205B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520620A5 (enExample) | ||
| JP2019533722A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| EP4370146A2 (en) | Lipidated peptide inhibitors of interleukin-23 receptor | |
| JPWO2019107530A5 (enExample) | ||
| JPWO2019156137A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| US11130790B2 (en) | Cell penetrating peptides that inhibit IRF5 nuclear localization | |
| CN103459419B (zh) | 具有抗炎活性的基于人乳铁蛋白的肽 | |
| JP2014521684A5 (enExample) | ||
| TWI455721B (zh) | 癌疫苗組合物 | |
| JP2012176978A5 (enExample) | ||
| JP2016509011A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2015532307A5 (enExample) | ||
| JP2019513752A5 (enExample) | ||
| US10206976B2 (en) | Protein particles comprising disulfide crosslinkers and uses related thereto | |
| MY205028A (en) | Protein for treatment of inflammatory diseases | |
| JP2019508175A5 (enExample) | ||
| AU2023204392A1 (en) | Cyclic prosaposin peptides and uses thereof | |
| JP2011528334A5 (enExample) | ||
| JP2017519763A5 (enExample) | ||
| JP2019526261A5 (enExample) | ||
| JP2014515595A5 (enExample) |